Matthew Bird PhD

Matthew Bird is Team Leader of Abzena’s bioconjugation group specialising in the development of Abzena’s ThioBridge™ ADC linker technology, he has worked in Abzena’s bioconjugation group since 2010 following his PhD from University of Reading and work as a process chemist at AstraZeneca.